Here's What Key Metrics Tell Us About Steris (STE) Q2 Earnings

For the quarter ended September 2025, Steris (STE) reported revenue of $1.46 billion, up 9.9% over the same period last year. EPS came in at $2.47, compared to $2.14 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.43 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +3.78%, with the consensus EPS estimate being $2.38.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Healthcare: $1.03 billion versus $1.01 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.Revenues- Healthcare Products- Consumables: $374.2 million versus $357.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.Revenues- Healthcare Products- Capital Equipment: $259.4 million compared to the $268.96 million average estimate based on three analysts. The reported number represents a change of +3.9% year over year.Revenues- Healthcare Products- Service: $400.1 million versus $374.76 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.Revenues- Life Sciences: $145 million versus $137.24 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.3% change.Revenues- Applied Sterilization Technologies (AST): $281.5 million compared to the $281.02 million average estimate based on three analysts. The reported number represents a change of +9.7% year over year.Revenues- Life Sciences- Service: $35.8 million versus $36.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.Revenues- Life Sciences- Capital Equipment: $31.9 million versus $27.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +38.6% change.Revenues- Life Sciences- Consumables: $77.2 million versus $71.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7% change.Operating income / (loss)- Healthcare: $259.5 million compared to the $239.46 million average estimate based on two analysts.Operating income / (loss)- Corporate and Other: $-109.9 million versus the two-analyst average estimate of $-106.78 million.Operating income / (loss)- Applied Sterilization Technologies (AST): $127.6 million versus $132.54 million estimated by two analysts on average.View all Key Company Metrics for Steris here>>>Shares of Steris have returned +0.1% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks